- Trials with a EudraCT protocol (385)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
385 result(s) found for: Cardiovascular Condition.
Displaying page 1 of 20.
EudraCT Number: 2013-003000-39 | Sponsor Protocol Number: CL2-38844-010 | Start Date*: 2014-03-20 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844 versus placebo in patients with chronic heart failure and left ventricular systolic d... | |||||||||||||
Medical condition: Patients with chronic heart failure and left ventricular systolic dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) SK (Completed) EE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001076-11 | Sponsor Protocol Number: CTQJ230A12301 | Start Date*: 2019-12-19 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with establishe... | |||||||||||||
Medical condition: Cardiovascular Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Restarted) AT (Ongoing) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SK (Trial now transitioned) IT (Ongoing) GR (Ongoing) PT (Trial now transitioned) SE (Trial now transitioned) NL (Ongoing) BG (Ongoing) BE (Trial now transitioned) NO (Trial now transitioned) SI (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001640-56 | Sponsor Protocol Number: PI12/01866 | Start Date*: 2014-01-31 | |||||||||||
Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba | |||||||||||||
Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio... | |||||||||||||
Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017242-30 | Sponsor Protocol Number: D5132C00001 | Start Date*: 2010-12-06 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Sali... | |||||||||||||
Medical condition: Myocardial Infarction, Cardiovascular Death, Atherothombosis, Stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (Completed) DE (Completed) HU (Completed) RO (Completed) CZ (Completed) SK (Completed) PL (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) NO (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017594-37 | Sponsor Protocol Number: CVAL489K2305 | Start Date*: 2011-06-29 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multicenter, open-label 18 month study to evaluate the long-term safety and tolerability of valsartan in children 6 to 17 years of age with hypertension and with or without chronic kidney disease. | ||
Medical condition: Hypertension. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) FI (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002455-26 | Sponsor Protocol Number: IRON-CMR | Start Date*: 2014-09-20 |
Sponsor Name:Karolinska Institute | ||
Full Title: The use of intravenous Iron oxide as a contrast agent for cardiac magnetic resonance imaging. | ||
Medical condition: Cardiovascular diseases: Acute myocardial infarction, chronic myocardial infarction, myocardial ischemia, myocarditis, diffuse myocardial fibrosis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003406-10 | Sponsor Protocol Number: BC21144 | Start Date*: 2007-12-13 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Ar... | |||||||||||||
Medical condition: Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) DE (Completed) IT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002799-42 | Sponsor Protocol Number: CAPstatin2013 | Start Date*: 2014-03-27 |
Sponsor Name:Dipartimento di Medicina Interna e Specialità Mediche - Policlinico Umberto I - Sapienza Università di Roma | ||
Full Title: Statins in the prevention of myocardial damage in pneumonia | ||
Medical condition: Patients hospitalized with community-acquired pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004376-11 | Sponsor Protocol Number: AZM-MD-302 | Start Date*: 2012-05-15 | |||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||
Full Title: A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizat... | |||||||||||||
Medical condition: Ventricular arrhythmia in patients with implantable cardioverter-defibrillator (ICD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001738-29 | Sponsor Protocol Number: RGHT000502 | Start Date*: 2009-03-20 |
Sponsor Name:Belfast Health and Social Care Trust | ||
Full Title: Renin angiotensin Aldosterone (RAAS) axis, endothelial function and hypertension: diagnostic strategies and therapeutic role of potassium supplementation | ||
Medical condition: We are seeking to determine the effects of potassium supplementation vs placebo for 6 weeks on the renin-angiotensin-aldosterone axis and also endothelial function in subjects with 10-20% 10 year ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004136-36 | Sponsor Protocol Number: 1002-040 | Start Date*: 2016-06-14 | ||||||||||||||||||||||||||
Sponsor Name:Esperion Therapeutics, Inc. | ||||||||||||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC-1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY C... | ||||||||||||||||||||||||||||
Medical condition: Treatment of high cardiovascular risk patients (heterozygous familial hypercholesterolemia [HeFH] and atherosclerotic cardiovascular diseases [ASCVD]) with hyperlipidemia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) GB (Completed) DE (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000046-19 | Sponsor Protocol Number: RIVAROXHFA3001/BAY59-7939/16302 | Start Date*: 2013-08-23 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Sub... | |||||||||||||
Medical condition: Prevention of death, heart attack and stroke in patients with chronic heart failure and significant coronary artery disease following a hospitalization for exacerbation of heart failure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) DE (Completed) NL (Completed) BG (Completed) PL (Completed) HU (Completed) SE (Completed) IT (Completed) GB (Completed) EE (Completed) LT (Completed) PT (Completed) DK (Completed) LV (Completed) SK (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002980-24 | Sponsor Protocol Number: ASA-001 | Start Date*: 2014-07-01 |
Sponsor Name:IRCCS San Raffaele di Roma | ||
Full Title: Comparative study to evaluate the effect on platelet aggregation of two different doses (20 and 40 mg) of acetylsalicylic acid administered sublingually compared to the dose of 100 mg of acetylsali... | ||
Medical condition: Patients with moderate/high cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001924-16 | Sponsor Protocol Number: FDY-5301-302 | Start Date*: 2022-04-13 | |||||||||||
Sponsor Name:Faraday Pharmaceuticals, Inc. | |||||||||||||
Full Title: IOCYTE AMI-3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY-5301 in Patients with an Anterior ST-Elevation Myocardial Infarction | |||||||||||||
Medical condition: Anterior ST-Elevation Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) SK (Ongoing) ES (Ongoing) PL (Ongoing) PT (Ongoing) CZ (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003871-19 | Sponsor Protocol Number: srhths01 | Start Date*: 2006-09-19 |
Sponsor Name:Salford Royal Hospital | ||
Full Title: A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease | ||
Medical condition: Secondary hyperparathyroidism in renal failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004115-12 | Sponsor Protocol Number: 1002-050 | Start Date*: 2017-05-17 | ||||||||||||||||||||||||||
Sponsor Name:Esperion Therapeutics, Inc. | ||||||||||||||||||||||||||||
Full Title: A Multicenter Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg | ||||||||||||||||||||||||||||
Medical condition: Treatment of high cardiovascular risk patients (heterozygous familial hypercholesterolemia [HeFH] and atherosclerotic cardiovascular diseases [ASCVD]) with hyperlipidemia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) PL (Completed) GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-004163-39 | Sponsor Protocol Number: HSJD-LIT-05 | Start Date*: 2005-11-14 |
Sponsor Name:Hospital Sant Joan de Déu | ||
Full Title: Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism ... | ||
Medical condition: Polycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat exces... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003218-36 | Sponsor Protocol Number: 82646 | Start Date*: 2023-06-05 |
Sponsor Name:Radboudumc | ||
Full Title: The safety of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction and the effect on intramyocardial haemorrhage | ||
Medical condition: Acute myocardial infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003997-33 | Sponsor Protocol Number: NOAH-AFNET6 | Start Date*: 2016-11-18 | |||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork] | |||||||||||||
Full Title: Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes | |||||||||||||
Medical condition: Atrial fibrillation (AF) is one cause of stroke. Stroke rate is increased in patients with atrial high rate episodes (AHRE, an early stage of AF) as well, even if stroke rates are lower when compa... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) BG (Completed) SE (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) GR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000737-40 | Sponsor Protocol Number: BAY12-8039/11826 | Start Date*: 2012-02-20 |
Sponsor Name:Bayer HealthCare Pharmaceuticals | ||
Full Title: Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients | ||
Medical condition: No medical condition specified as the purpose of this study is to describe the pharmacokinetics of moxifloxacin in children for future antibiotic treatment. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.